Tenet Healthcare (NYSE:THC) Given New $252.00 Price Target at Guggenheim

Tenet Healthcare (NYSE:THC) had its target price trimmed by Guggenheim from $283.00 to $252.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on THC. Leerink Partners lifted their target price on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. Truist Financial raised their price objective on Tenet Healthcare from $240.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Barclays upped their target price on shares of Tenet Healthcare from $240.00 to $257.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Wall Street Zen lowered shares of Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Tenet Healthcare in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.94.

Tenet Healthcare Stock Up 3.5%

Shares of NYSE:THC traded up $6.11 during midday trading on Friday, hitting $183.23. 3,327,802 shares of the company’s stock were exchanged, compared to its average volume of 1,400,520. The company has a debt-to-equity ratio of 1.96, a current ratio of 1.36 and a quick ratio of 1.68. Tenet Healthcare has a 12 month low of $145.27 and a 12 month high of $247.21. The company has a market cap of $16.05 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 1.32 and a beta of 1.30. The stock has a 50 day moving average price of $207.31 and a 200-day moving average price of $204.17.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating the consensus estimate of $4.21 by $0.61. The business had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, sell-side analysts anticipate that Tenet Healthcare will post 17.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Paola M. Arbour sold 6,500 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total value of $1,549,795.00. Following the transaction, the executive vice president directly owned 29,291 shares of the company’s stock, valued at approximately $6,983,853.13. The trade was a 18.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider R. Scott Ramsey sold 8,017 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $232.70, for a total transaction of $1,865,555.90. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 46,517 shares of company stock valued at $10,943,111. 0.81% of the stock is owned by insiders.

Institutional Trading of Tenet Healthcare

A number of large investors have recently bought and sold shares of the company. Diversify Wealth Management LLC raised its stake in shares of Tenet Healthcare by 31.0% in the first quarter. Diversify Wealth Management LLC now owns 3,409 shares of the company’s stock valued at $614,000 after buying an additional 806 shares during the period. Citizens Financial Group Inc. RI grew its stake in shares of Tenet Healthcare by 11.4% during the 1st quarter. Citizens Financial Group Inc. RI now owns 1,175 shares of the company’s stock worth $222,000 after acquiring an additional 120 shares during the period. Fifth Third Bancorp raised its stake in Tenet Healthcare by 3,984.0% in the 1st quarter. Fifth Third Bancorp now owns 45,659 shares of the company’s stock valued at $8,616,000 after acquiring an additional 44,541 shares during the period. Candriam S.C.A. lifted its holdings in Tenet Healthcare by 13.2% during the first quarter. Candriam S.C.A. now owns 202,158 shares of the company’s stock valued at $38,149,000 after purchasing an additional 23,557 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its position in Tenet Healthcare by 10.4% during the first quarter. Sequoia Financial Advisors LLC now owns 1,496 shares of the company’s stock worth $282,000 after purchasing an additional 141 shares during the period. 95.44% of the stock is owned by hedge funds and other institutional investors.

Key Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q1 earnings beat and solid profitability — Tenet reported $4.82 EPS, well ahead of consensus, and showed healthy margins and ROE; investors favor the earnings beat even though revenue was roughly in-line. Tenet Healthcare (THC) Q1 Earnings Top Estimates
• Positive Sentiment: Strategic growth via ASC acquisitions — Tenet deployed ~$125M to acquire seven ambulatory surgery centers in Q1 and signals more M&A in the outpatient space, supporting revenue diversification and higher-margin outpatient growth. Tenet deployed $125M on 7 ASC acquisitions in Q1, eyes more deals
• Positive Sentiment: Operational momentum in procedures and robotics — The company is seeing double‑digit joint replacement growth and expanding robotic programs across ASCs/hospitals, evidence that its outpatient acuity push is producing revenue mix benefits longer term. Double-digit joint replacement growth
• Neutral Sentiment: Analysts trimmed price targets but kept Buy/Outperform/Overweight ratings — Multiple firms cut PTs (RBC to $236, Guggenheim to $252, Wells Fargo to $213, KeyCorp to $225) while retaining positive ratings, which gives the stock continued sell‑side endorsement but signals more conservative valuation assumptions. Analyst price target coverage (Benzinga summaries) TickerReport coverage
• Neutral Sentiment: Market commentary and investor takeaways — Several pieces are advising investors to weigh analyst views and the company’s outpatient strategy at current levels; these articles are shaping investor positioning rather than delivering new fundamental news. Seeking Alpha: Investor commentary
• Negative Sentiment: Revenue softness and admissions‑mix headwinds — Management flagged admissions mix and external disruptions as reasons revenue missed expectations modestly; that weak revenue signal tempers the EPS beat and is the main near-term risk. Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.